Aurobindo Pharma Limited announced a significant development post its Board of Directors meeting held on November 4, 2026. The company has approved the standalone and consolidated unaudited financial results for the second quarter and half-year ended September 30, 2026. A key highlight from the meeting is the declaration of an interim dividend of 700%, equivalent to Rs. 7.00 per equity share. Additionally, the Board has approved proposals for a scheme of amalgamation and transfer of ownership of a Russian subsidiary.
Aurobindo Pharma Board Meeting Outcomes
In a significant announcement following its Board of Directors meeting on November 4, 2026, Aurobindo Pharma Limited has declared a substantial interim dividend and approved its financial results. The company’s Board considered and approved the standalone and consolidated unaudited financial results for the second quarter and half-year ending September 30, 2026. These results have been submitted along with the limited review reports from the statutory auditors.
Interim Dividend Declaration
A major decision from the meeting was the approval of an interim dividend of 700%, translating to Rs. 7.00 per equity share of Re. 1/- each. The company has set November 11, 2026, as the record date for this dividend payment, with the dividend expected to be paid on or before November 20, 2026.
Amalgamation and Restructuring Approvals
Further strengthening its corporate structure, the Board also gave its nod to a proposal for a Scheme of Amalgamation. This scheme involves the merger of Auroactive Pharma Private Limited with Apitoria Pharma Private Limited, both wholly owned subsidiaries of Aurobindo Pharma. The proposal is slated to be filed with the Hon’ble NCLT, Hyderabad. In a related move, the transfer of ownership of Auro Pharma LLC, Russia, from Auroactive Pharma Private Limited to Auropharm Overseas Limited, another wholly owned subsidiary, has also been approved by the respective Boards.
Director Re-appointment
Based on the recommendation of the Nomination and Remuneration/Compensation Committee, the Board has approved the re-appointment of Mr. Mangalam Ramasubramanian Kumar as a Director (Non-executive and Independent). This re-appointment is for a second term of 5 years, effective from April 1, 2027, following the completion of his current term on March 31, 2027. This re-appointment is subject to the approval of the members through a postal ballot.
Financial Highlights (Standalone)
The unaudited standalone financial results show the company’s performance for the quarter and half-year ended September 30, 2026. Key figures include total income, total expenses, and profit before tax from continuing operations. For the half-year ended September 30, 2026, revenue from continuing operations stood at ₹59,444.8 million. Profit before tax from continuing operations was ₹19,790.3 million.
Consolidated Financial Performance
On a consolidated basis, for the half-year ended September 30, 2026, Aurobindo Pharma reported total revenue of ₹1,94,136.4 million. The profit before tax from continuing operations was ₹32,429.5 million. The company also reported total comprehensive income of ₹23,119.3 million for the same period.
Cash Flow Statement Insights
The standalone cash flow statement indicates a net cash flow generated from operating activities of ₹9,224.9 million for the half-year ended September 30, 2026. The consolidated cash flow statement shows a net cash generated from operating activities of ₹32,831.4 million for the same period. The company utilized ₹12,170.5 million for financing activities on a standalone basis, primarily due to buybacks and borrowings.
Source: BSE
